Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Moderna's Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson's drug

CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.

Fortune

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times

Novo is Building a Strong Base to Address Unmet Needs in Diabetes and Obesity Drugs

Novo (formerly Novo Nordisk) is partnering with Anthropic to use AI to speed up drug discovery.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

NVO Stock Alert: What to Know as Novo Partners With Anthropic on Drug Discovery

Novo Nordisk partners with Anthropic on drug discovery. Here’s what the strategic alliance means for NVO shares.

Barchart

Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk

Novartis and Novo Nordisk heart drugs failed large trials weeks apart. Analysts say the results could cool investment in cardiovascular drug development.

Medical Daily

NVO Stock Alert: What to Know as Novo Nordisk Rebrands to 'Novo'

Novo Nordisk stock rallies as the company rebrands as Novo and introduces a new visual identity. Here’s what it means for NVO shares.

Barchart

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

Reason

Novo Nordisk Halts Two More Heart Failure Trials of Ziltivekimab After a Data Committee Found Futility

Novo Nordisk stopped the HERMES and ATHENA heart failure trials of ziltivekimab for futility, ending study treatment for enrolled patients.

Medical Daily

Weight-loss pill "Wegovy" available in German pharmacies from 1 September

The weight-loss pill Wegovy is now available in German pharmacies. Its active ingredient semaglutide increases satiety and the adult dose costs 170 to 280 euros.

Euronews

Philadelphia Cycling Classic men: Tim Torn Teutenberg sprints to first pro victory from late breakaway

Ronald Donaldson is second and Jonas Rutsch takes third in revived American race

Cycling News

Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit

Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This…

The Economic Times

'Game-changer' GLP-1s could fix America's obesity crisis—but 2 inequalities stand in the way

Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't "pencil out" too often.

Fortune

Prescription Drug Prices Fell 3.1 Percent Over the Year, but That Number Measures Less Than You Think

Prescription drug prices posted their steepest annual drop since 1963. Here is what the index actually measures and what it leaves out.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Waist Size Flags Heart Risk in Adults Whose BMI Looks Normal, Large Pooled Analysis Finds

A pooled analysis of 259,388 adults found waist measures flagged elevated heart risk in many people whose BMI looked entirely normal.

Cycling News

Czech Tour: Riley Sheehan squeezes past Ben Turner to win tight stage 1 sprint

US rider takes first leader's jersey of four-day stage race

The Economic Times

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also received approval for the UK market. The weight-loss drug market is seeing increased…

Medical Daily

A Major Anti-Inflammatory Heart Drug Trial Failed, Testing a Leading Theory About Artery Disease

Novo Nordisk's ziltivekimab lowered inflammation but did not reduce heart attacks, strokes, or cardiovascular deaths in a 6,300-patient trial.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.

International Business Times

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

MarketBeat

The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic

Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.

The Economic Times

Global Market: European shares climb as earnings, US-Iran diplomacy lift sentiment

European stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased for investors. Novo Nordisk shares fell despite an improved outlook due to drug trial setbacks. Sandoz surged on strong second-quarter net sales, boosting healthcare stocks. Siemens Energy also gained following record…

The Economic Times

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity…

International Business Times

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

Benzinga

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Red BullBoraHansgrohe

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.